Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantation

Bone Marrow Transplantation volume 54, pages 1651–1661 (2019)Cite this article

Subjects

Abstract

Survival after allogeneic stem cell transplantation (allo-HSCT) has improved, but so have long-term sequelae. We studied risk factors for fractures and impaired bone health in allo-HSCT patients in the Basel HSCT registry from 01/2003 to 12/2014 using cox proportional models adjusted for age, gender and Karnofsky Index. Our primary endpoint was the incidence of fractures. Out of 652 patients, 32 (5.0%) had a new fracture after transplantation (yearly incidence rate of 1.6%, 95% Confidence Interval [95%CI] 1.1–2.3%) and 325 (49.8%) had low bone mineral density (yearly incidence rate of 13.1%, 95%CI 11.6–14.8%), including 36.0% with osteopenia and 13.8% with osteoporosis. We found vitamin D deficiency during follow-up (Hazard Ratio [HR] 1.25, 95%CI 1.11–1.41, p < 0.001), hyperthyroidism before transplantation (HR 4.85, 95%CI 1.05–22.54, p = 0.044), cumulative years of immunosuppressant exposure (HR 1.23, 95%CI 1.07–1.41, p = 0.004 for steroidal and HR 1.09, 95%CI 1.01–1.18, p = 0.025 for non-steroidal drugs) and graft-versus-host disease (acute HR 1.24, 95%CI 1.11–1.40, p < 0.001; chronic HR 2.82, 95%CI 1.12–7.13, p = 0.028) to be significantly associated with fractures. Patients undergoing HSCT are at increased risk of fractures, which is associated with various disease and treatment-specific factors. Early identification of patients at risk may help to improve preventive measures.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51:786–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Rovo A, Daikeler T, Halter J, Heim D, Tsakiris DA, Stern M, et al. Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor. Haematologica. 2011;96:150–5.

    Article  PubMed  Google Scholar 

  3. Anandi P, Jain NA, Tian X, Wu CO, Pophali PA, Koklanaris E, et al. Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors. Bone Marrow Transplant. 2016;51:1101–6.

    Article  CAS  PubMed  Google Scholar 

  4. Yao S, Smiley SL, West K, Lamonica D, Battiwalla M, McCarthy PL Jr., et al. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16:1130–7.

    Article  CAS  PubMed  Google Scholar 

  5. Tauchmanova L, Colao A, Lombardi G, Rotoli B, Selleri C. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2007;92:4536–45.

    Article  CAS  PubMed  Google Scholar 

  6. Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G, et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant. 2001;7:257–64.

    Article  CAS  PubMed  Google Scholar 

  7. Pundole XN, Barbo AG, Lin H, Champlin RE, Lu H. Increased incidence of fractures in recipients of hematopoietic stem-cell transplantation. J Clin Oncol. 2015;33:1364–70.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003;101:3373–85.

    Article  CAS  PubMed  Google Scholar 

  9. Serio B, Pezzullo L, Fontana R, Annunziata S, Rosamilio R, Sessa M, et al. Accelerated bone mass senescence after hematopoietic stem cell transplantation. Transl Med UniSa. 2013;5:7–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Schulte CM, Beelen DW. Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood. 2004;103:3635–43.

    Article  CAS  PubMed  Google Scholar 

  11. Schimmer AD, Minden MD, Keating A. Osteoporosis after blood and marrow transplantation: clinical aspects. Biol Blood Marrow Transplant. 2000;6(2A):175–81.

    Article  CAS  PubMed  Google Scholar 

  12. Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F. Development and use of FRAX in osteoporosis. Osteoporos Int. 2010;21(Suppl 2):S407–13.

    Article  PubMed  Google Scholar 

  13. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed.) Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 196.

  14. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.

    CAS  PubMed  Google Scholar 

  15. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.

    Article  PubMed  Google Scholar 

  16. Jagasia MHGH, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389–401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001.

    Article  PubMed  Google Scholar 

  17. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9.

    Article  Google Scholar 

  18. Lin JN, Chen HJ, Yang CH, Lai CH, Lin HH, Chang CS, et al. Risk of osteoporosis and pathologic fractures in cancer patients who underwent hematopoietic stem cell transplantation: a nationwide retrospective cohort study. Oncotarget. 2017;8:34811–9.

    PubMed  PubMed Central  Google Scholar 

  19. McClune BL, Polgreen LE, Burmeister LA, Blaes AH, Mulrooney DA, Burns LJ, et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant. 2011;46:1–9.

    Article  CAS  PubMed  Google Scholar 

  20. Savani BN, Donohue T, Kozanas E, Shenoy A, Singh AK, Childs RW, et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:517–20.

    Article  PubMed  Google Scholar 

  21. Gandhi MK, Lekamwasam S, Inman I, Kaptoge S, Sizer L, Love S, et al. Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol. 2003;121:462–8.

    Article  PubMed  Google Scholar 

  22. Pundole X, Murphy WA, Ebede CC, Karim E, Manocha S, Don-Pedro D, et al. Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Arch Osteoporos. 2018;13:38.

    Article  PubMed  Google Scholar 

  23. Melton LJ 3rd, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20:487–93.

    Article  PubMed  Google Scholar 

  24. Pundole X, Cheema HI, Petitto GS, Lopez-Olivo MA, Suarez-Almazor ME, Lu H. Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: a systematic review and meta-analysis. Bone Marrow Transplant. 2017;52:663–70.

    Article  CAS  PubMed  Google Scholar 

  25. Petropoulou AD, Porcher R, Herr AL, Devergie A, Brentano TF, Ribaud P, et al. Prospective assessment of bone turnover and clinical bone diseases after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;89:1354–61.

    Article  PubMed  Google Scholar 

  26. Grigg A, Butcher B, Khodr B, Bajel A, Hertzberg M, Patil S, et al. An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial. Bone Marrow Transplant. 2017;52:1288–93.

    Article  CAS  PubMed  Google Scholar 

  27. Buchs N, Helg C, Collao C, Chapuis B, Slosman D, Bonjour JP, et al. Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss. Osteoporos Int. 2001;12:880–6.

    Article  CAS  PubMed  Google Scholar 

  28. Hari P, DeFor TE, Vesole DH, Bredeson CN, Burns LJ. Intermittent zoledronic acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1361–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported in part by the Swiss National Science Foundation (SNSF Professorship, PP00P3_150531 / 1) and the Research Council of the Kantonsspital Aarau (1410.000.044)

Author information

Author notes

  1. These authors contributed equally: Annic Baumgartner, Michèle Moesch, Melanie Zumsteg

Authors and Affiliations

  1. Medical University Department, Clinic for Endocrinology/Metabolism/Clinical Nutrition, Kantonsspital Aarau, Aarau, Switzerland

    Annic Baumgartner, Michèle Moesch, Melanie Zumsteg, Tristan Struja, Selina Bernet, Beat Mueller & Philipp Schuetz

  2. Medical Faculty of the University of Basel, Basel, Switzerland

    Michèle Moesch, Melanie Zumsteg, Beat Mueller & Philipp Schuetz

  3. Division of Hematology, University Hospital Basel, Basel, Switzerland

    Michael Medinger & Jakob Passweg

  4. Division of Hematology, Medical University Clinic of Kantonsspital Aarau, Aarau, Switzerland

    Mario Bargetzi

Authors
  1. Annic Baumgartner
    View author publications

    Search author on:PubMed Google Scholar

  2. Michèle Moesch
    View author publications

    Search author on:PubMed Google Scholar

  3. Melanie Zumsteg
    View author publications

    Search author on:PubMed Google Scholar

  4. Tristan Struja
    View author publications

    Search author on:PubMed Google Scholar

  5. Selina Bernet
    View author publications

    Search author on:PubMed Google Scholar

  6. Michael Medinger
    View author publications

    Search author on:PubMed Google Scholar

  7. Beat Mueller
    View author publications

    Search author on:PubMed Google Scholar

  8. Jakob Passweg
    View author publications

    Search author on:PubMed Google Scholar

  9. Mario Bargetzi
    View author publications

    Search author on:PubMed Google Scholar

  10. Philipp Schuetz
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Philipp Schuetz.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baumgartner, A., Moesch, M., Zumsteg, M. et al. Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantation. Bone Marrow Transplant 54, 1651–1661 (2019). https://doi.org/10.1038/s41409-019-0484-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41409-019-0484-6

This article is cited by

Search

Advanced search

Quick links